All In MedTech

FDA Clearance Tracker · P140031-S141

Edwards SAPIEN 3 Ultra RESILIA Transcatheter Heart Valve

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Jul 28, 2022 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Jul 28, 2022

Approved

Time to decision

87 days

Received May 2, 2022. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Normal 180 Day Track

Device class

Class III

The decision

FDA number
P140031-S141
Device name
Edwards SAPIEN 3 Ultra RESILIA Transcatheter Heart Valve
Applicant location
Irvine, CA
Received
May 2, 2022
Decided
Jul 28, 2022
Decision
Approved
Supplement type
Normal 180 Day Track
Reason for supplement
Change Design/Components/Specifications/Material
Original approval
P140031

Device type

Device class
Class III

Every decision under product code NPT

FDA's approval statement

As written in FDA's record.

Approval for the Edwards SAPIEN 3 Ultra RESILIA Transcatheter Heart Valve.

Source documents

Other decisions for Edwards Lifesciences, LLC

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

7 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.